Research interests, publications, awards, and web links 

Professional profile

Dr Miles Parkes is Lead for Gastroenterology at Addenbrooke's Hospital in Cambridge. He qualified from Oxford University (BA, 1st Class) and Imperial College, London (MBBS) and worked in London for three years before returning to Oxford for specialist training. He was appointed as a consultant gastroenterologist at Addenbrooke's in 2001, and as Director of Gastroenterology and Endoscopy in 2003. He continues as head of this department and is clinical lead for inflammatory bowel disease. 

Dr Parkes holds a Bronze National Clinical Excellence Award in recognition of his services to the NHS.

Research interests include new therapies in gastrointestinal disease and the molecular genetic basis of Crohn's disease and ulcerative colitis. Dr Parkes heads an internationally renowned IBD research group and chairs the UK IBD genetics research consortium. He has played a leading role in several landmark studies identifying multiple susceptibility genes for Crohn's disease and ulcerative colitis. This work has mainly been funded by the Wellcome Trust, the MRC and Crohn's and Colitis UK, and has resulted in a large number of publications and articles in high impact journals including Nature, Cell and Nature Genetics. He has also authored chapters for many textbooks, including the Oxford Textbook of Medicine which is widely regarded at the doctors bible, and is regularly invited to teach and lecture at home and at conferences in Europe, the USA and Australia.

Awards

BA 1st Class - University of Oxford

MRC Research Training Fellowship 1996-1999

National Clinical Excellence Award - Bronze 2010 and 2015

Invited lectures - British Society of Gastroenterology, American Gastroenterology Association, European Crohn's and Colitis Organization, United European Gastroenterology Week, Gastroenterology Society of Australia,

 

Summary of recent publications

Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal A, Monaco CL, Zhao G, Fleshner P, Stappenbeck TS, McGovern DP, Keshavarzian A, Mutlu EA, Sauk J, Gevers D, Xavier RJ, Wang D, Parkes M, Virgin HW. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015 Jan 29;160(3):447-60

Lim YC, Corbett G, Parkes M, Cameron EA. 'High definition': not all it appears. Gut. 2014 May;63(5):863-4.

Raine T, Liu JZ, Anderson CA, Parkes M*, Kaser A* (*denotes shared senior author). Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated disease. Gut. 2014 May 5. doi: 10.1136/gutjnl-2013-306657. [Epub ahead of print]

Lee JC, Espéli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ, Roberts R, Viatte S, Fu B, Peshu N, Hien TT, Phu NH, Wesley E, Edwards C, Ahmad T, Mansfield JC, Gearry R, Dunstan S, Williams TN, Barton A, Vinuesa CG; UK IBD Genetics Consortium, Parkes M, Lyons PA, Smith KG. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell. 2013 Sep 26;155(1):57-69

Ellinghaus D, Zhang H, Zeissig S, Lipinski S, Till A, .., Annese V, Halfvarson J, D'Amato M, Daly MJ, Nothnagel M, Karlsen TH, Subramani S, Rosenstiel P, Schreiber S, Parkes M*, Franke A* (*denotes shared senior author). Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies. Gastroenterology. 2013 Aug;145(2):339-47

Wellcome Trust Case Control Consortium. Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet. 2012 Dec;44(12):1294-301.

Jostins L*, Ripke S* .. Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions shape genetic risk for inflammatory bowel disease. Nature, 2012 Nov 491(7422):119-24.

Cooke J, Zhang H, Greger L, Silva AL, Massey D, Dawson C, Metz A, Ibrahim A, Parkes M. Mucosal genome-wide methylation changes in inflammatory bowel disease. Inflamm Bowel Dis. 2012 Nov;18(11):2128-37.

Hewitt RE, Pele LC, Tremelling M, Metz A, Parkes M, Powell JJ. Immuno-inhibitory PD-L1 can be induced by a peptidoglycan/NOD2 mediated pathway in primary monocytic cells and is deficient in Crohn's patients with homozygous NOD2 mutations. Clin Immunol. 2012 May;143(2):162-9.

Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, Smith KG. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest. 2011 Oct 3;121(10):4170-9

Franke A, McGovern DP … Hakonarson H, Daly MJ, Parkes M. Genome-Wide Meta-Analysis Increases to 71 the Number of Confirmed Crohn's Disease Susceptibility Loci. Nature Genetics. 2010;42(12):1118-25.

Anderson CA, … Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics. 2011 Mar;43(3):246-52.

Sharkey L, Bredin F, Nightingale A, Parkes M. The use of Ciclosporin A in Acute Severe Ulcerative Colitis: Long term outcomes. J Crohn's and Colitis 2011 Apr;5(2):91-4.

Lewis GJ, Massey DCO, … Lee JC, Berzuini C, Parkes M. Genetic association between NLRP3 variants and Crohn's disease does not replicate in large UK panel. Inflamm Bowel Dis. 2011 Jun;17(6):1387-9.

Al-Hilou H, Carroll N, Jah A, Davies S, Parkes M. A rare cause of duodenal stricture. BMJ Case Rep. 2011 Feb 8;2011.

Wellcome Trust Case Control Consortium. Craddock N, Hurles ME, …, Parkes M, Rahman N, Todd JA, Samani NJ, Donnelly P. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010 Apr 1;464(7289):713-20.

Liu JZ, Tozzi F, Waterworth DM, … Parkes M, Satsangi J, Caulfield M, Munroe PB, Farrall M, Dominiczak A, Worthington J, Thomson W, Eyre S, Barton A; Wellcome Trust Case Control Consortium, Mooser V, Francks C, Marchini J. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nature Genetics. 2010 May;42(5):436-40.

The UK IBD Genetics Consortium and WTCCC2 Genome-wide association study of ulcerative colitis identifies three susceptibility loci, including HNF4A. Nature Genetics 2009 Dec;41(12):1330-4.

Anderson CA… Mathew CG, Satsangi J, Parkes M. Investigation of Crohn's disease risk loci in Ulcerative Colitis further defines their molecular relationship. Gastroenterology 2009 Feb;136(2):523-9.

Wiesner M, Naylor SJ, Copping A, Furlong A, Lynch AG, Parkes M, Hunter JO. Symptom classification in irritable bowel syndrome as a guide to treatment. Scand J Gastroenterol. 2009;44(7):796-803

Massey DC, Bredin F, Parkes M Use of sirolimus (rapamycin) to treat refractory Crohn's disease; a case report. Gut 2008 Sep;57(9):1294-6

Barrett JC, …, Parkes M, Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics. 2008 Aug;40(8):955-62.

Fisher SA, …, Parkes M, Satsangi J. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nature Genetics 2008 Jun;40(6):710-2.

Parkes M, Barrett JC, Prescott NJ, …. Sanderson J, Jewell DP, Satsangi J, Mansfield JC; Wellcome Trust Case Control Consortium, Cardon L, Mathew CG. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genetics. 2007 Jul;39(7):830-2

Wellcome Trust Case Control Consortium [Primary Investigators: Bentley D, …Parkes M, Pembrey M, Rahman N, Samani NJ, Stratton MR, Todd JA, Worthington J] Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447, 661-678

Tremelling M, Cummings F, Fisher SA, Mansfield J, Gwilliam R, Keniry A, Nimmo ER, Drummond H, Onnie CM, Prescott NJ, Sanderson J, Bredin F, Berzuini C, Forbes A, Lewis CM, Cardon L, Deloukas P, Jewell D, Mathew CG, Parkes M, Satsangi J. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology. 2007 May;132(5):1657-64.

Tremelling M, Waller S, Bredin F and Parkes M. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. Inflamm Bowel Dis. 2006 Mar;12(3):178-84

Tremelling M, Hancock L, Bredin F, Sharpstone D, Bingham S and Parkes M. Complex insertion/deletion polymorphism in NOD1 (CARD4) is not associated with inflammatory bowel disease susceptibility in East Anglia panel. Inflamm Bowel Dis. 2006 Oct;12(10):967-71.

Waller S, Tremelling M, Bredin F, Godfrey L, Howson J and Parkes M. Evidence for association of OCTN genes and IBD5 with ulcerative colitis. Gut. 2006 Jun;55(6):809-14.

Hugot JP, Zaccaria I, Cavanaugh J, Yang H, Vermeire S, Lappalainen M, Schreiber S, Annese V, Jewell D, Fowler E, Brant S, Silverberg M, Cho J, Rioux J, Satsangi J, Parkes M, for the IBD International Genetics Consortium. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol. 2007 Jun;102(6):1259-67

Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment Pharmacol Ther. 2007 Aug 1;26(3):421-30

M D Robertson, M Parkes, B F Warren, D J P Ferguson, K G Jackson, D P Jewell, K N Frayn. Mobilisation of enterocyte fat stores by oral glucose in humans Gut 2003;52:834-839

Cavanaugh J and the International IBD Genetics Consortium. International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16. Am J Hum Genet. 2001;68(5):1165.

Parkes M, Barmada M, Satsangi J, Weeks D, Jewell DP, Duerr R. Linkage heterogeneity between ulcerative colitis and Crohn's disease at IBD2 locus. Am. J. Hum. Genet. 2000; 67: 1605-1610

Parkes M, Booth JC, Pillai G, Mee AS. Do steroids help jaundice caused by primary sclerosing cholangitis? J Clin Gastroenterol. 2001 Oct;33(4):319-22.

Kyo K, Parkes M, Takei Y, Nishimori H, Vyas P, Satsangi J, Simmons J, Nagawa H, Baba S, Jewell D, Muto T, Lathrop GM, Nakamura Y. Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. Hum Mol Genet. 1999 Feb;8(2):307-11.

Parkes M, Satsangi J, Jewell D. Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. Clin Exp Immunol. 1998 Jul;113(1):28-32.

Louis E, Satsangi J, Roussomoustakaki M, Parkes M, Fanning G, Welsh K, Jewell D. Cytokine gene polymorphisms in inflammatory bowel disease. Gut. 1996 Nov;39(5):705-10

Parkes M, Satsangi J, Lathrop GM, Bell JI, Jewell DP. Susceptibility loci in inflammatory bowel disease. Lancet. 1996 Dec 7;348(9041):1588.

Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh KI, et al. Two-stage genome-wide search in inflammatory bowel disease: evidence for susceptibility loci on chromosomes 3, 7 and 12. Nature Genetics 1996;14:199.

 

Selected Reviews and Chapters

Parkes M. Cortes A, van Heel D, Brown M. Analysis Article: Genetic insights into common pathways and complex relationships among immune mediated diseases. Nature Reviews Genetics 2013;14(9):661-73

Parkes M. The genetics universe of Crohn's disease and ulcerative colitis. Dig Dis. 2012;30 Suppl 1:78-81.

Parkes M. Evidence from genetics for a role of autophagy and innate immunity in IBD pathogenesis. Dig Dis. 2012;30(4):330-3.

Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases.Gut. 2011 Dec;60(12):1739-53.

Lee JC, Parkes M. Genome-wide association studies and Crohn's disease.Brief Funct Genomics. 2011 Mar;10(2):71-6

Parkes M 'Crohn's Disease' chapter in Oxford Textbook of Medicine, Eds David A. Warrell, Timothy M. Cox, John D. Firth, Edward J. Benz, Jr. Oxford University Press 2010 and 2016 (new edition).

Parkes M 'Which will take us further in IBD - study of coding variation or epigenetics?' In 'Clinical Dilemmas in IBD'. Eds Irving P, Rampton D and Shanahan F. 2010. Blackwell.

Stappenbeck TS, Rioux JD, Mizoguchi A, Saitoh T, Huett A, Darfeuille-Michaud A, Wileman T, Mizushima N, Carding S, Akira S, Parkes M, Xavier RJ. Crohn disease: A current perspective on genetics, autophagy and immunity. Autophagy. 2010 Feb 17;7(2).

Zhang H, Massey D, Tremelling M, Parkes M. Genetics of inflammatory bowel disease: clues to pathogenesis. Br Med Bull. 2008;87:17-30.

Massey DC, Parkes M. Leading article. Common pathways in Crohn's disease and other inflammatory diseases revealed by genomics. Gut. 2007 Nov;56(11):1489-92

Massey DC, Parkes M. Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn's disease. Autophagy. 2007 Nov-Dec;3(6):649-51

Tremelling M, Parkes M. Genome-wide association scans identify multiple confirmed susceptibility loci for Crohn's disease: Lessons for study design. Inflamm Bowel Dis. 2007 Dec;13(12):1554-60.

Tremelling M, Parkes M. Genetics of IBD - Clinical and Therapeutic Applications. In 'Clinical Dilemmas in IBD'. Eds Irving P, Rampton D and Shanahan F. 2006. Blackwell.

Baburajan B, Parkes M. The genetics of inflammatory bowel disease. Hosp Med. 2003 Oct;64(10):599-602

Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006 Apr 1;23(7):841-55

Parkes M, Jewell D. Ulcerative colitis and Crohns disease: molecular genetics and clinical implications. Expert Rev Mol Med. 2001 Nov 19;2001:1-18

Parkes M, Jewell DP. Review article: the management of severe Crohn's disease. Aliment Pharmacol Ther. 2001 May;15(5):563-73.

 

Web Links

www.wtccc.org.uk

www.ibdgenetics.org

www.ibdresearch.org.uk

www.immunology.cam.ac.uk/directory/profile.php?milesparkes